Auto-immune toxiity of Sars-Cov2 vaccine in patients with thymic epithelial tumours: a prospective analysis from the tyme net

Background: There are many assumptions that raise fears of auto-immune toxicity of SARS-COV-2 vaccine in patients affected by Thymic epithelial tumours (TETs). TETs are associated with paraneoplastic autoimmune disorders and vaccine autoimmune cross reactivity is associated with many syndromes such as Guillain-Barre, multiple sclerosis, demyelinating neuropathies. Moreover, a crossreaction between SARS-Cov-2 anti protein spike antibodies and several tissue proteins has been reported. Material and methods: We are prospectively collecting data on safety and new onset or recurrence of autoimmune disorders in patients with TETs who received SARSCOV-2 vaccine and are treated in referral centres of the TYME network. Patients with both Thymoma [T] and Thymic carcinoma [TC], with and without pre-existing autoimmune disorders, treated with chemotherapy, immunotherapy, TKI or just in follow up are included in the analysis. Association between epidemiological-clinical factors and risk of general Adverse Events (AEs), immune-related AEs and worsening of autoimmune disorders will be assessed. Results: Preliminary data from the first 20 patients (14 TC and 4 T) suggest that the administration of SARSCOV-2 vaccines is well tolerated, with no safety signals nor reactivation or new onset of autoimmune diseases observed. E – Covid-19 85 Prospective data collection of all TETs patients treated in referral centres of the TYME network is ongoing and will be presented at the time of AIOM congress. Conclusions: Preliminary data suggest that the administration of SARS-COV-2 vaccines is safe and well tolerated in patients affected by TETs. A comprehensive characterization of general and immune-related safety profile of SARSCOV-2 vaccines in such rare oncological population, enriched for potential risk factors for AEs, is ongoing.